Visterra Closes $46.7 Million Series C Financing to Advance Pipeline of Precision Antibody-Based Biological Medicines – Company Focused on Lead Product Candidates, VIS410, for Treatment of Hospitalized Patients with In - Company C - Document - PDFSEARCH.IO

First Page	Meta Content
	Visterra Closes $46.7 Million Series C Financing to Advance Pipeline of Precision Antibody-Based Biological Medicines – Company Focused on Lead Product Candidates, VIS410, for Treatment of Hospitalized Patients with In Add to Reading List Document Date: 2017-10-04 20:40:08 Open Document File Size: 119,67 KB Share Result on Facebook

Visterra Closes $46.7 Million Series C Financing to Advance Pipeline of Precision Antibody-Based Biological Medicines – Company Focused on Lead Product Candidates, VIS410, for Treatment of Hospitalized Patients with InAdd to Reading List